WO2004105696A3 - Combination therapy for the treatment of neoplasms - Google Patents

Combination therapy for the treatment of neoplasms Download PDF

Info

Publication number
WO2004105696A3
WO2004105696A3 PCT/US2004/016314 US2004016314W WO2004105696A3 WO 2004105696 A3 WO2004105696 A3 WO 2004105696A3 US 2004016314 W US2004016314 W US 2004016314W WO 2004105696 A3 WO2004105696 A3 WO 2004105696A3
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasms
treatment
combination therapy
kits
methods
Prior art date
Application number
PCT/US2004/016314
Other languages
French (fr)
Other versions
WO2004105696A2 (en
Inventor
Margaret S Lee
James M Nichols
Amy Beth Wilson
Grant R Zimmermann
Original Assignee
Combinatorx Inc
Margaret S Lee
James M Nichols
Amy Beth Wilson
Grant R Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc, Margaret S Lee, James M Nichols, Amy Beth Wilson, Grant R Zimmermann filed Critical Combinatorx Inc
Priority to JP2006533367A priority Critical patent/JP2007500231A/en
Priority to EP04753186A priority patent/EP1631290A2/en
Priority to US10/558,136 priority patent/US20070179152A1/en
Publication of WO2004105696A2 publication Critical patent/WO2004105696A2/en
Publication of WO2004105696A3 publication Critical patent/WO2004105696A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features compositions, methods, and kits for the treatment of neoplasms.
PCT/US2004/016314 2003-05-23 2004-05-21 Combination therapy for the treatment of neoplasms WO2004105696A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006533367A JP2007500231A (en) 2003-05-23 2004-05-21 Combination treatment to treat neoplasms
EP04753186A EP1631290A2 (en) 2003-05-23 2004-05-21 Combination therapy for the treatment of neoplasms
US10/558,136 US20070179152A1 (en) 2003-05-23 2004-05-21 Combination therapy for the treatment of neoplasms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47320703P 2003-05-23 2003-05-23
US60/473,207 2003-05-23

Publications (2)

Publication Number Publication Date
WO2004105696A2 WO2004105696A2 (en) 2004-12-09
WO2004105696A3 true WO2004105696A3 (en) 2005-02-10

Family

ID=33490574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016314 WO2004105696A2 (en) 2003-05-23 2004-05-21 Combination therapy for the treatment of neoplasms

Country Status (4)

Country Link
US (1) US20070179152A1 (en)
EP (1) EP1631290A2 (en)
JP (1) JP2007500231A (en)
WO (1) WO2004105696A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004795A2 (en) * 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
AU2011253561B2 (en) * 2005-08-22 2013-11-21 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP1919480B1 (en) * 2005-08-22 2013-01-16 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2420239B1 (en) * 2007-04-13 2015-01-14 Southern Research Institute Clomipramine as anti-angiogenic agent
CN102458382B (en) 2009-05-12 2015-03-18 咖勒尼卡公司 Oil-in-water emulsion of mometasone and propylene glycol
EP2674158B9 (en) * 2012-06-14 2015-11-18 Szegedi Tudományegyetem Treatment and prevention of cardiac arrhythmias
US10507208B2 (en) 2015-10-12 2019-12-17 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
EP3173081B1 (en) 2015-11-30 2019-09-25 Pécsi Tudományegyetem Desethylamiodarone for use in cancer treatment
KR20240046762A (en) 2021-10-05 2024-04-09 아사히 가세이 가부시키가이샤 Method for producing high purity diarylcarbonate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474997A (en) * 1993-01-27 1995-12-12 Sepracor, Inc. Methods and compositions of (2R,4S) itraconazole for treating fungal yeast and dermatophyte infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474997A (en) * 1993-01-27 1995-12-12 Sepracor, Inc. Methods and compositions of (2R,4S) itraconazole for treating fungal yeast and dermatophyte infections

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACHIVERS OF INTERNAL MED., vol. 139, April 1989 (1989-04-01), USA, pages 425 - 438 *
DATABASE MEDLINE [online] YOSHIDA J. ET AL.: "Antitumor effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo", accession no. STN Database accession no. 2004278254 *
DATABASE TOXCENTER [online] LEAK D. ET AL.: "Control of refractory cardaic arrhythmias with amiodarone", accession no. STN Database accession no. 1979:302 *
EU. J. PHARMACOL., vol. 492, no. 2-3, 25 May 2004 (2004-05-25), pages 103 - 112 *

Also Published As

Publication number Publication date
WO2004105696A2 (en) 2004-12-09
US20070179152A1 (en) 2007-08-02
JP2007500231A (en) 2007-01-11
EP1631290A2 (en) 2006-03-08

Similar Documents

Publication Publication Date Title
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2006119295A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2007059041A3 (en) Combinations and methods of using an immunomodulatory oligodeoxynucleotide
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005085266A3 (en) Macrocyclic compounds and methods of making and using the same
ZA200804550B (en) Methods, compositions, and kits for the treatment of medical conditions
WO2005048948A3 (en) Urea derivatives as kinase modulators
WO2002040000A3 (en) Use of cci-779 as an antineoplastic agent
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004069160A3 (en) Chemical compounds
WO2005118610A3 (en) Macrocyclic compounds and methods of making and using the same
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
WO2005124563A9 (en) Compounds and kits for treating muscle disorders and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006533367

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004753186

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004753186

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10558136

Country of ref document: US

Ref document number: 2007179152

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10558136

Country of ref document: US